Rapport Therapeutics (RAPP) Institutional Ownership

Of the 103 institutional investors that purchased Rapport Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP V LLC ($7.14M), ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), Vestal Point Capital LP ($1.11M), Perceptive Advisors LLC ($1.02M), and Polar Capital Holdings Plc ($1.00M).

Institutional investors have bought a total of 10,423,642 shares in the last 24 months. This purchase volume represents approximately $305.55M in transactions.

Of the 25 institutional investors that sold Rapport Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: T. Rowe Price Investment Management Inc. ($561.22K), Siren L.L.C. ($412K), UBS Group AG ($331.71K), Adage Capital Partners GP L.L.C. ($300K), Alliancebernstein L.P. ($299.07K), Price T Rowe Associates Inc. MD ($220.78K), and Cormorant Asset Management LP ($165K).

Institutional investors have sold a total of 2,688,464 shares in the last 24 months. This volume of shares sold represents approximately $81.48M in transactions.